Effects of treatments for symptoms of painful diabetic neuropathy: systematic review
- 11 June 2007
- Vol. 335 (7610) , 87-90A
- https://doi.org/10.1136/bmj.39213.565972.ae
Abstract
Objective To evaluate the effects of treatments for the symptoms of painful diabetic neuropathy.Design Systematic review.Data sources Articles (English and full text) on double blind randomised trials found by searching with the key words anticonvulsant, antidepressant, non-steroidal anti-inflammatory drugs, tramadol, opioid, ion channel blocker, diabetic neuropathy, diabetic peripheral neuropathy, peripheral neuropathy, and neuropathy. The search included Medline, Embase, EMB reviews-AP Journal club, and the Cochrane central register of controlled trials.Study selection Randomised controlled trials comparing topically applied and orally administered drugs with a placebo in adults with painful diabetic neuropathy.Data extraction Data were extracted to examine quality of methods, characteristics of studies and patients, efficacy, and side effects. The primary outcome was dichotomous information for 50% or moderate reduction of pain. Secondary outcomes were 30% reduction of pain and withdrawals related to adverse events.Results Odds ratios were calculated for achievement of 30%, 50%, or moderate pain relief and for withdrawals related to adverse effects. Twenty five reports were included and seven were excluded. The 25 included reports compared anticonvulsants (n=1270), antidepressants (94), opioids (329), ion channel blockers (173), N-methyl-D-aspartate antagonist (14), duloxetine (805), capsaicin (277), and isosorbide dinitrate spray (22) with placebo. The odds ratios in terms of 50% pain relief were 5.33 (95% confidence interval 1.77 to 16.02) for traditional anticonvulsants, 3.25 (2.27 to 4.66) for newer generation anticonvulsants, and 22.24 (5.83 to 84.75) for tricylic antidepressants. The odds ratios in terms of withdrawals related to adverse events were 1.51 (0.33 to 6.96) for traditional anticonvulsants, 2.98 (1.75 to 5.07) for newer generation anticonvulsants, and 2.32 (0.59 to 9.69) for tricylic antidepressants. Insufficient dichotomous data were available to calculate the odds ratios for ion channel blockers.Conclusion Anticonvulsants and antidepressants are still the most commonly used options to manage diabetic neuropathy. Oral tricyclic antidepressants and traditional anticonvulsants are better for short term pain relief than newer generation anticonvulsants. Evidence of the long term effects of oral antidepressants and anticonvulsants is still lacking. Further studies are needed on opioids, N-methyl-D-aspartate antagonists, and ion channel blockers.This publication has 26 references indexed in Scilit:
- Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetesDiabetic Medicine, 2004
- A Multicenter Study on the Prevalence of Diabetic Neuropathy in ItalyDiabetes Care, 1997
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996
- Natural History of Peripheral Neuropathy in Patients with Non-Insulin-Dependent Diabetes MellitusNew England Journal of Medicine, 1995
- Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year studyDiabetes Research and Clinical Practice, 1995
- The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes MellitusNew England Journal of Medicine, 1993
- The Effect of Long-Term Intensified Insulin Treatment on the Development of Microvascular Complications of Diabetes MellitusNew England Journal of Medicine, 1993
- A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic populationDiabetologia, 1993
- Mexiletine in the Treatment of Diabetic NeuropathyDiabetes Care, 1992
- The Prevalence of Symptomatic, Diabetic Neuropathy in an Insulin-treated PopulationDiabetes Care, 1985